title: [Osteoporosis, bisphosphonates and jaws osteochemonecrosis].
abstract: Bisphosphonates are widely used in the treatment of nonmalignant bone disease like osteoporosis, Paget's disease and malignant disease like malignant hypercalcemia, osteolytic metastasis from breast and prostate cancer and multiple myeloma. Jaws osteonecrosis is described since 2003 and is more often associated with the intraveinous use than oral use. Higher risk of osteonecrosis is noted after 3 years of osteoporosis treatment. The precipitating event is often a tooth extraction or other invasive procedure. There is no effective treatment for this pathology. Careful oral examination is necessary before prescribing bisphosphonates and dental treatment must be achieved before the initiation of treatment.
authors.affiliation: Service de Stomatologie et de Chirurgie Maxillo-Faciale, Hôpital Erasme, Bruxelles. michele.magremanne@ulb.ac.be
authors.forename: M
authors.initials: M
authors.lastname: Magremanne
mesh_terms: D004164:Diphosphonates / Q000009:adverse effects*; D005882:Gingival Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000473:pathology; D006801:Humans; D007049:Iatrogenic Disease; D007571:Jaw Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D010020:Osteonecrosis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D010024:Osteoporosis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D011859:Radiography; D012307:Risk Factors
chemical_list: D004164:Diphosphonates